tDCS in Chronic Migraine With Medication Overuse (Edisom) (Edisom)
Primary Purpose
Migraine Disorders, Medication Overuse Headache
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
tDCS
Sponsored by
About this trial
This is an interventional treatment trial for Migraine Disorders
Eligibility Criteria
Inclusion Criteria:
- chronic migraine with medication overuse according to the International Headache Society criteria. Diagnosis was confirmed on the basis of a daily headache diary that all eligible patients filled out in the last month prior to the enrollment. Patients should have failed at least two prophylaxis therapies. Written informed consent.
Exclusion Criteria:
- known diagnosis of major depression or other major psychiatric disorders identified after psychiatric consultation, cardiac pace maker, clips for previous head surgery, cochlear implant, history of epilepsy, known idiopathic intracranial hypertension, harmful alcohol consumption, pregnancy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Placebo Comparator
Arm Label
anodal tDCS
cathodal tDCS
sham tDCS
Arm Description
anodal tDCS stimulation
cathodal tDCS stimulation
sham tDCS stimulation (stopped after 30 seconds)
Outcomes
Primary Outcome Measures
days of headache per month (long-term)
no. patients with 50% reduction of days of headache per month
Secondary Outcome Measures
days of headache per month (mid-term)
no. patients with 50% reduction of days of headache per month
analgesic intake per month
percentage of reduction of analgesic intake per month compared to baseline
disability
Migraine Disability Assessment (MIDAS). MIDAS-score
0-:5 low disability
6-10: MILD disability 11-20: Moderate disability more than 2:0 Severe disability.
catastrophizing attitude
Pain Catastrophizing Scale (PCS) pathological more than 30 (total score) no cut off for the subscales
depression
Beck Depression Inventory (BDI) score more than 7
state and trait anxiety
Spielberger questionnaires STAIY1-Y2 ; score between 20-80
dependence attitude
Leed questionnaire score
Under 10: low dependency
10-22: medium dependency
more than 22: high dependency
allodynia intensity
Allodynia Symptoms Checklist
Full Information
NCT ID
NCT04228809
First Posted
January 4, 2020
Last Updated
February 12, 2020
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
University of Milano Bicocca
1. Study Identification
Unique Protocol Identification Number
NCT04228809
Brief Title
tDCS in Chronic Migraine With Medication Overuse (Edisom)
Acronym
Edisom
Official Title
Long-term Efficacy of Transcranial Direct Current Stimulation in Chronic Migraine With Medication Overuse: a Phase III, Placebo Controlled, Randomised Clinical Trial (Edisom)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
December 1, 2015 (Actual)
Primary Completion Date
June 30, 2017 (Actual)
Study Completion Date
May 30, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
University of Milano Bicocca
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Transcranial direct current stimulation (tDCS) was suggested to provide beneficial effects in chronic migraine (CM), a condition often associated with medication overuse (MO) for which no long-term therapy is available.
Detailed Description
We conducted a randomized controlled trial to assess long-term efficacy of tDCS. Adults diagnosed with CM and MO were assigned to receive in a 1:1:1 ratio anodal, cathodal, or sham tDCS daily for five consecutive days, along with standardized drug withdrawal protocol with intravenous administration of dexamethasone 4 mg and ademetionine 200 mg in saline solution, and oral bromazepam 1.5 mg three times daily.
Primary outcome was 50% reduction of days of headache per month at 12 months. Co-secondary outcomes were 50% reduction of days of headache per month at 6 months, reduction of analgesic intake per month, and change in disability and quality of life, catastrophizing, depression, state and trait anxiety, dependence attitude and allodynia intensity. Patients were not allowed to take any migraine prophylaxis drug for the entire study period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine Disorders, Medication Overuse Headache
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
sham
Allocation
Randomized
Enrollment
135 (Actual)
8. Arms, Groups, and Interventions
Arm Title
anodal tDCS
Arm Type
Experimental
Arm Description
anodal tDCS stimulation
Arm Title
cathodal tDCS
Arm Type
Active Comparator
Arm Description
cathodal tDCS stimulation
Arm Title
sham tDCS
Arm Type
Placebo Comparator
Arm Description
sham tDCS stimulation (stopped after 30 seconds)
Intervention Type
Device
Intervention Name(s)
tDCS
Intervention Description
transcranial direct current stimulation
Primary Outcome Measure Information:
Title
days of headache per month (long-term)
Description
no. patients with 50% reduction of days of headache per month
Time Frame
12 months
Secondary Outcome Measure Information:
Title
days of headache per month (mid-term)
Description
no. patients with 50% reduction of days of headache per month
Time Frame
6 months
Title
analgesic intake per month
Description
percentage of reduction of analgesic intake per month compared to baseline
Time Frame
6 and 12 months
Title
disability
Description
Migraine Disability Assessment (MIDAS). MIDAS-score
0-:5 low disability
6-10: MILD disability 11-20: Moderate disability more than 2:0 Severe disability.
Time Frame
6 and 12 months
Title
catastrophizing attitude
Description
Pain Catastrophizing Scale (PCS) pathological more than 30 (total score) no cut off for the subscales
Time Frame
6 and 12 months
Title
depression
Description
Beck Depression Inventory (BDI) score more than 7
Time Frame
6 and 12 months
Title
state and trait anxiety
Description
Spielberger questionnaires STAIY1-Y2 ; score between 20-80
Time Frame
6 and 12 months
Title
dependence attitude
Description
Leed questionnaire score
Under 10: low dependency
10-22: medium dependency
more than 22: high dependency
Time Frame
6 and 12 months
Title
allodynia intensity
Description
Allodynia Symptoms Checklist
Time Frame
6 and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
chronic migraine with medication overuse according to the International Headache Society criteria. Diagnosis was confirmed on the basis of a daily headache diary that all eligible patients filled out in the last month prior to the enrollment. Patients should have failed at least two prophylaxis therapies. Written informed consent.
Exclusion Criteria:
known diagnosis of major depression or other major psychiatric disorders identified after psychiatric consultation, cardiac pace maker, clips for previous head surgery, cochlear implant, history of epilepsy, known idiopathic intracranial hypertension, harmful alcohol consumption, pregnancy.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32536270
Citation
Grazzi L, Usai S, Bolognini N, Grignani E, Sansone E, Tramacere I, Maravita A, Lauria G. No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial. Cephalalgia. 2020 Oct;40(11):1202-1211. doi: 10.1177/0333102420931050. Epub 2020 Jun 14.
Results Reference
derived
Learn more about this trial
tDCS in Chronic Migraine With Medication Overuse (Edisom)
We'll reach out to this number within 24 hrs